Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study

被引：1

作者：

Kuboki, Y. ^{[1
]}

Pietrantonio, F. ^{[2
]}

Salvatore, L. ^{[3
]}

Esaki, T. ^{[4
]}

Modest, D. P. ^{[5
]}

Paez, D. ^{[6
]}

Taieb, J. ^{[7
]}

Ruiz, E. ^{[8
,9
]}

Kim, T. W. ^{[10
]}

Meriggi, F. A. ^{[11
]}

Cunningham, D. ^{[12
,13
]}

Yeh, K-H. ^{[14
]}

Chan, E. ^{[15
]}

Chao, J. ^{[16
]}

Strydom, N. ^{[17
]}

Saportas, Y. ^{[18
]}

Tran, Q. ^{[19
]}

Cremolini, C. ^{[20
]}

Fakih, M. ^{[21
]}

机构：

[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Fdn Policlin Univ Agostino Gemelli IRCC, Dipartimento Oncol, Rome, Italy

[4] Natl Hosp Org, Med Oncol, Kyushu Canc Ctr, Fukuoka, Japan

[5] Charite Univ Med Berlin, Dept Med Hematol Oncol & Tumorimmunol, Berlin, Germany

[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[7] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France

[8] INCAN Inst Nacl Cancerol, GI Oncol Dept, Ciudad De Mexico, Mexico

[9] INCAN Inst Nacl Cancerol, Translat Med Lab, Ciudad De Mexico, Mexico

[10] Univ Ulsan, Asan Med Ctr, Coll Med, Oncol Dept, Seoul, South Korea

[11] Fdn Poliambulanza Ist Osped, Oncol Dept, Brescia, Italy

[12] Inst Canc Res, Med Dept, Sutton, Surrey, England

[13] Royal Marsden Hosp, Sutton, Surrey, England

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[15] Amgen Inc, Global Dev, Thousand Oaks, CA USA

[16] Amgen USA, Oncol Therapeut Area, Seattle, WA USA

[17] Amgen Inc SSF, Clin Pharmacol, San Francisco, CA USA

[18] Amgen Headquarters USA, Global Safety, Thousand Oaks, CA USA

[19] Amgen Headquarters USA, Biostat, Thousand Oaks, CA USA

[20] AOU Pisana Stabilimento Santa Chiara, Polo Oncol, Pisa, Italy

[21] City Hope Comprehens Canc Ctr, Med Oncol Therapeut Res, Duarte, CA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

91MO

引用

页码：S1504 / S1505

页数：2

共 50 条

[1] Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
Pietrantonio, F.
Salvatore, L.
Esaki, T.
Modest, D. P.
Paez, D.
Taieb, J.
Karamouzis, M. V.
Ruiz, E.
Kim, T. W.
Kuboki, Y.
Meriggi, F. A.
Cunningham, D.
Yeh, K. H.
Chan, E.
Chao, J.
Strydom, N.
Saportas, Y.
Tran, Q.
Cremolini, C.
Fakih, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1266 - S1266
[2] Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
Hong, David S.
Kuboki, Yasutoshi
Yaeger, Rona
Strickler, John H.
Masuishi, Toshiki
Langer, Corey
Shergill, Ardaman
Kim, Edward
Hindoyan, Antreas
Tran, Qui
Mukundan, Lata
Chan, Emily
Anderson, Abraham
Fakih, Marwan G.
CANCER RESEARCH, 2023, 83 (07)
[3] Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto plus pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)
Fakih, Marwan
Salvatore, Lisa
Esaki, Taito
Modest, Dominik Paul
Lopez-Bravo, David Paez
Taieb, Julien
Karamouzis, Michalis
Ruiz-Garcia, Erika
Kim, Tae Won
Kuboki, Yasutoshi
Meriggi, Fausto Angelo
Cunningham, David
Yeh, Kun-Huei
Chan, Emily
Chao, Joseph
Tran, Qui
Cremolini, Chiara
Pietrantonio, Filippo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3510 - LBA3510
[4] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
Hong, David S.
Kuboki, Yasutoshi
Strickler, John H.
Fakih, Marwan
Houssiau, Helene
Price, Timothy Jay
Elez, Elena
Siena, Salvatore
Chan, Emily
Nolte-Hippenmeyer, Jane
Cardona, Panli
Tran, Qui
Masuishi, Toshiki
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
Paez, D.
Meriggi, F.
Cremolini, C.
Folprecht, G.
Korantzis, I.
Chan, E.
Tran, Q.
Fakih, M. G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S734
[6] A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301).
Kim, Tae Won
Price, Timothy
Grasselli, Julieta
Masuishi, Toshiki
Kwok, Gin Wai
Yalcin, Suayib
Obiozor, Cynthia Chinedu
Chan, Emily
Gokani, Priya
Sunakawa, Yu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS326 - TPS326
[7] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, Marwan G.
Salvatore, Lisa
Esaki, Taito
Modest, Dominik P.
Lopez-Bravo, David P.
Taieb, Julien
Karamouzis, Michalis V.
Ruiz-Garcia, Erika
Kim, Tae-Won
Kuboki, Yasutoshi
Meriggi, Fausto
Cunningham, David
Yeh, Kun-Huei
Chan, Emily
Chao, Joseph
Saportas, Yaneth
Tran, Qui
Cremolini, Chiara
Pietrantonio, Filippo
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2125 - 2139
[8] Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Siena, S.
Yamaguchi, K.
Ruffinelli Rodriguez, J. C.
Corral de la Fuente, E.
Kuboki, Y.
Cremolini, C.
Victoria Ruiz, I.
Elez Fernandez, M. E.
Strickler, J. H.
Furqan, M.
Bashir, B.
Nduka, C.
Hippenmeyer, J.
Chan, E.
Xia, C.
Masuishi, T.
ANNALS OF ONCOLOGY, 2024, 35 : S429 - S430
[9] Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial
Kuboki Y.
Fakih M.
Strickler J.
Yaeger R.
Masuishi T.
Kim E.J.
Bestvina C.M.
Kopetz S.
Falchook G.S.
Langer C.
Krauss J.
Puri S.
Cardona P.
Chan E.
Varrieur T.
Mukundan L.
Anderson A.
Tran Q.
Hong D.S.
Nature Medicine, 2024, 30 (1) : 265 - 270
[10] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Kuboki, Y.
Yaeger, R.
Fakih, M.
Strickler, J. H.
Masuishi, T.
Kim, E. J-H.
Bestvina, C. M.
Langer, C. J.
Krauss, J. C.
Puri, S.
Cardona, P.
Chang, E. K.
Tran, Q.
Hong, D. S.
ANNALS OF ONCOLOGY, 2022, 33 : S1445 - S1446

← 1 2 3 4 5 →